

RNA, wherein said recombinant polynucleotide hybridizes under stringent conditions to a polynucleotide having a sequence complementary to SEQ. ID NO:224.

2 ~~84~~. (New) The mammalian cell of claim ~~83~~¹, wherein the recombinant polynucleotide encodes a full-length naturally occurring human telomerase reverse transcriptase.

3 ~~85~~. (New) The mammalian cell of claim ~~83~~¹, which expresses said encoding sequence at the mRNA level, as measured by PCR amplification.

crit
4 ~~86~~. (New) The mammalian cell of claim ~~83~~¹, which expresses said encoding sequence at the protein level, as measured by immunoassay.

5 ~~87~~. (New) The mammalian cell of claim ~~83~~¹, which has telomerase activity, as measured in a primer elongation assay.

6 ~~88~~. (New) The mammalian cell of claim ~~83~~¹, which is a human cell.

8 ~~89~~. (New) The mammalian cell of claim ~~83~~¹, which is a stem cell.

7 ~~90~~. (New) The mammalian cell of claim ~~88~~⁶, which is a stem cell.

REMARKS

I. Status of Claims

Claims 46-81 are currently pending, with claims 1-45 and claim 82 having been previously canceled without prejudice or disclaimer (see amendments filed February 25, 1998 and November 23, 1998). Claims 46-81 are canceled upon entry of this amendment. These claims are canceled without prejudice or disclaimer; Applicant retains the right to reintroduce these claims into the instant application or to pursue these claims in a subsequent application.

New claims 83-90 are introduced with this amendment. These claims are supported throughout the specification. Examples of such support can be found as indicated in the following table.

281

D